Latest Asset Impairments News

Treasury Wine Estates is reshaping its global operations into four regional divisions to sharpen market execution and efficiency. The company reports improved third-quarter sales in China and the US, bolstered by luxury brand Penfolds, while securing $300 million in new debt to strengthen liquidity beyond $1 billion by fiscal 2026 end.

DGL Group Limited has agreed to sell two chlor-alkali manufacturing plants for $2.5 million, well below their carrying value, reflecting a $5.3 million impairment charge. The sale aligns with the company’s strategic focus on core operations and is not expected to materially affect ongoing activities.

Novo Resources Corp. reported a net loss of CAD 22.4 million for 2025, slightly improving from the previous year, while securing a $5.9 million capital raise to support ongoing exploration and operations.

Image Resources NL is set to record significant non-cash impairments totalling around A$61 million in its 2025 financial results, reflecting challenges from weaker mineral sands prices and a stronger Australian dollar.

Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

HALO Technologies reports a strategic pivot towards APAC growth and a UK business model overhaul, alongside a 16% revenue decline and increased net loss in FY25.

Halo Technologies Holdings Ltd posted a $17.4 million loss for 2025, widening from $14.5 million the previous year, as revenue fell 16%. The company completed a $3.9 million rights issue and announced a strategic pivot in its UK operations.

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Steadfast Group Limited reported a solid half-year result for December 2025, with underlying net profit after tax rising 7% to $137.5 million and a fully franked interim dividend declared. The insurer intermediary also increased its gearing capacity to support ongoing growth.

Viva Energy Group Limited reported a significant net loss for 2025, driven by retail asset impairments, yet underlying profits and strategic investments signal resilience and a clear path forward.